PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant

(American Association for Cancer Research) Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news